Information on this page is provided as a guide and may change. Please verify details directly with the treatment center or other appropriate source before making care decisions.

Institution Logo

University of Colorado Cancer Center

Kidney Cancer Program

Primary Address

1665 Aurora Ct, First Floor
Aurora, CO, 80045
Appointment Scheduling Phone: (720) 848-0170
Program Website

Satellite Locations

UCHealth Lone Tree Medical Center

Lone Tree, CO

UCHealth Highlands Ranch Hospital

Highlands Ranch, CO

Key Contacts

Medical Oncology:
Dr. Corbin Eule
Medical Oncology:
Dr. Elaine Lam
Medical Oncology:
Dr. Jenny Xiang
Medical Oncology:
Dr. Laura Graham
Medical Oncology:
Dr. Elizabeth Kessler
Medical Oncology:
Dr. Thomas Flaig
Urologic Surgery:
Dr. Janet Kukreja
Urologic Surgery:
Dr. David Strauss
Urologic Surgery:
Dr. Nicholas Cost
Urologic Surgery:
Dr. Paul Maroni
Urologic Surgery:
Dr. Kit Yuen
Urologic Surgery:
Dr. Mitchell Hayes
Radiation Oncology:
Dr. Tyler Robin MD, PhD
Radiation Oncology:
Dr. Sameer Nath
Patient Navigator & Appointments:
Call (720) 848-0170

Volume

Metrics reflect this center’s demonstrated experience across key areas of kidney cancer care.

Kidney Cancer Surgery Volume

High

Clear Cell Kidney Cancer Diagnosis Volume

Medium

Non–Clear Cell Kidney Cancer Diagnosis Volume

Medium

Clinical Trial Participation Volume

Very High

Radiation & Ablation Procedure Volume

High

About these ratings

Volume and expertise levels are determined using standardized thresholds established by the Kidney Cancer Association and updated annually. Metrics are based on available data and may not reflect the full scope of a center’s capabilities or activity. These metrics are intended to help patients identify centers with demonstrated experience in kidney cancer care.

Types of Services Offered

Clinical Trials End of Life Services Genetic Counseling Infusion Center Molecular Testing Multidisciplinary Clinic Oncology Urgent Care Clinic Palliative & Supportive Care Patient Case Discussions / Tumor Boards Precision Medicine Survivorship Clinics Interventional Radiology Medical Oncology Pain Management Palliative Care Pathology Radiation Oncology Radiology Urologic Surgery

Kidney Cancer Types & Expertise

Chromophobe RCC Clear Cell RCC Collecting Duct RCC FH-deficient RCC Papillary RCC Renal Medullary Carcinoma Sarcomatoid Translocation RCC Tuberous Sclerosis–associated RCC Unclassified RCC VHL-associated RCC Bilateral Kidney Tumors Complex Recurrent Cases Cystic Renal Tumors Hereditary Syndromes Kidney Transplant Recipients Pregnancy Solitary Kidney Young Adult (age 18-50)

Special Programs, Recognitions & Outcomes

American College of Surgeons Accredited Cancer Program Government-Funded Research Member of Kidney Cancer Consortium NCI Designated Cancer Center

Consortium Member

VHL Alliance

Research Programs

Clinical Multi-Institutional Collaboration Population-Based Research Lab Translational

Multi-Institutional Collaborations

UCHealth
University of Colorado School of Medicine
Children's Hospital Colorado
NCCN member institutions
Alliance for Clinical Trials in Oncology
ECOG-ACRIN
SWOG
NCTN
Multicenter GU oncology trials
Industry-sponsored RCC trials
Collaborations with other NCI-designated cancer centers

Patient Resources & Support Services

Art Therapy Fertility Preservation Counseling Financial Navigators Interpreter Services Lodging / Long-Term Housing Lymphedema Therapy Music Therapy Nurse Navigators Nutrition Services / Dietician Occupational Therapy On-site Dispensing / Pharmacy Parking Assistance (valet or concierge) Pastoral / Spiritual Care Patient Navigators Peer Support Options Physical Therapy Psychiatrists / Psychologists Remote Monitoring Tools Social Workers / Counselors Transportation Service Wellness Center

Insurance Carriers

Accepted

  • Aetna
  • Anthem Blue Cross Blue Shield
  • Cigna
  • UnitedHealthcare
  • Humana
  • Kaiser Permanente (select agreements)
  • Health Net
  • Rocky Mountain Health Plans
  • MultiPlan / PHCS
  • First Health
  • Cofinity
  • Medicare
  • Medicare Advantage
  • Colorado Medicaid
  • Colorado Access
  • TRICARE
  • TRICARE for Life
  • VA Community Care
  • TriWest
  • Connect for Health Colorado plans
  • Workers' Compensation
  • International Insurance
  • Self-Pay

Insurance information is provided as a guide and may change. Participation can vary by plan, location, and individual coverage. Please contact the treatment center and your insurance provider directly to confirm that your specific insurance plan is currently accepted and to understand any applicable coverage requirements or costs.

Open Clinical Trials

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden. A decrease in the size of the tumor thrombus can potentially lead to decrease in surgical complications, improve patient related health outcomes, and improve long term outcomes such as progression free survival and overall survival.

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving pembrolizumab and tivozanib together may work better than pembrolizumab alone in treating patients with RCC.

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.
Request an Appointment